Introduction
============

Lung cancer is the most common type of malignant tumor and the leading cause of cancer-associated mortality worldwide ([@b1-etm-0-0-7357],[@b2-etm-0-0-7357]). Small cell lung cancer (SCLC) accounts for 15--20% of all lung cancer cases and is characterized by rapid growth and early metastatic spread ([@b3-etm-0-0-7357]). Of all newly diagnosed patients with SCLC, \~70% present with advanced disease and require systemic chemotherapy. In such cases, clinicians must promptly initiate treatment. However, although SCLC is sensitive to chemotherapy, with initial response rates of ≥60%, the 5-year overall survival rate is \<5% ([@b4-etm-0-0-7357]). In the last decades, SCLC therapy and prognosis have not significantly improved and no novel drugs have been approved in the recent years ([@b5-etm-0-0-7357]), although progress has been made in the characterization of the genetic landscape of SCLC ([@b6-etm-0-0-7357]--[@b8-etm-0-0-7357]). In addition to continued development of novel treatments, the determination of the optimal use of the existing chemotherapies to improve the survival rate of SCLC patients represents a major clinical challenge.

Several combinations of chemotherapeutics may be used to treat SCLC. However, the etoposide-cisplatin (EP) regimen remains the primary choice of treatment and no novel chemotherapeutic combinations have been identified to be superior to EP as the first-line therapy in SCLC patients ([@b9-etm-0-0-7357],[@b10-etm-0-0-7357]). However, certain cases of SCLC do not respond well to EP chemotherapy. Thus, the possibility to predict treatment outcomes for SCLC patients, particularly those at high risk of responding poorly to first-line chemotherapy, is of great interest. This may allow for pre-chemotherapy risk stratification in SCLC and enable clinicians to select a treatment tailored to each patient\'s individual risk profile.

To date, no biomarkers with the ability to indicate the clinical response of SCLC patients to treatment have been identified; 75% of patients with SCLC have ≥2 circulating tumor cells (CTCs)/7.5 ml peripheral venous blood. Thus, CTC detection may be used to determine the response to therapy ([@b11-etm-0-0-7357],[@b12-etm-0-0-7357]). However, the low CTC number in blood may affect the reproducibility of these tumor cell counts. Furthermore, the currently available serum tumor markers for lung cancer cannot be used to monitor SCLC, as they have relatively low sensitivity and specificity for cancer cells; these include neuron-specific enolase (NSE), New York esophageal squamous cell carcinoma 1 antibody, plasma fibrinogen, D-dimer, carcinoembryonic antigen (CEA) and progastrin-releasing peptide (ProGRP) ([@b13-etm-0-0-7357]--[@b15-etm-0-0-7357]). The identification of novel, cost-effective and accurate biomarkers is crucial for predicting the clinical response of SCLC patients to chemotherapy.

Previous radiological studies have performed large-scale data analyses to improve the utilization of imaging over the past decade. High-throughput medical image analysis has been performed for quantitative feature extraction. From the images, certain features are being extracted and converted into data, which may in turn be analyzed using a decision support system; this novel technology is known as radiomics ([@b16-etm-0-0-7357]). This method is particularly useful in solid tumors that are unevenly shaped. Radiomics is able to capture heterogeneity in a non-invasive and cost-effective way ([@b17-etm-0-0-7357]--[@b19-etm-0-0-7357]). In fact, it is more useful than biopsy in this regard, as it reveals heterogeneity across the entire tumor ([@b20-etm-0-0-7357]).

Computed tomography (CT) is the most commonly used imaging modality, it is able to quantify tissue density with a high resolution and provide clear tumor images through enhanced scanning ([@b19-etm-0-0-7357]). In recent years, radiomics research has greatly advanced with regard to CT image analysis. Previous studies have identified features associated with tumor histology ([@b21-etm-0-0-7357]--[@b23-etm-0-0-7357]), tumor staging ([@b24-etm-0-0-7357]), overall survival ([@b25-etm-0-0-7357],[@b26-etm-0-0-7357]) and gene mutations ([@b27-etm-0-0-7357]). However, to the best of our knowledge, no previous study has elucidated the prognostic value of radiomics in SCLC patients scheduled for first-line chemotherapy.

The aim of the present study was to identify a CT-based radiomics signature and investigate whether it is able to predict the clinical response of SCLC patients to first-line chemotherapy.

Materials and methods
=====================

### Patient selection

A total of 134 patients with SCLC histopathologically confirmed by fine-needle aspiration biopsy and received chemotherapy at Shandong Cancer Hospital Affiliated to Shandong University (Jinan, China) were recruited for the present study. The patient inclusion criteria were as follows: i) Chemotherapy between March 2015 and March 2017; ii) No treatment or operation prior to admission; and iii) two courses of standard EP chemotherapy. Subjects with a mixed SCLC pathology (n=3), as well as those who did not receive two courses of standard EP chemotherapy (n=5), no availability of double-enhanced CT images captured prior to and after chemotherapy (n=13) and those who were lost to follow-up (n=21) were excluded ([Fig. 1](#f1-etm-0-0-7357){ref-type="fig"}).

### Therapeutic process and grouping standard

A total of 92 patients with SCLC who received two cycles of EP chemotherapy were included in the present study (EP regimen: cisplatin at an accumulated dose of 80 mg/m^2^ IV for 3 days and 100 mg/m^2^ IV etoposide daily (days 1--3). The interval between the two cycles of EP chemotherapy was 18 days. A chest CT scan was performed during the week prior to treatment initiation and at 4 weeks following routine chemotherapy. In accordance with the New Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 ([@b28-etm-0-0-7357]), two experienced radiologists compared the CT imaging characteristics from all scans obtained prior to chemotherapy compared with the post-chemotherapy scans. Each radiologist evaluated the images in the same manner and any discrepancies were resolved by discussion until a consensus was reached. The patients were divided into the following groups: Response group (n=70) and no response (n=22) group. Those patients who achieved either a complete or a partial response were assigned to the response group, whereas those with stable disease or disease progression were assigned to the no response group ([@b29-etm-0-0-7357]).

### Clinicopathological factors

The potential clinicopathological factors associated with SCLC including age (\<60 years or ≥60 years), sex, tumor extent (limited or diffuse) ([@b30-etm-0-0-7357]), tumor (T)-stage, nodal (N)-stage, metastasis (M)-stage, tumor location (central or peripheral), smoking (yes or no), smoking period (≤10, 11--20, 21--30, or ≥30 years), smoking index (\<400 or ≥400) and tumor laboratory indicators \[ProGRP, \<54.8 or ≥54.8 ng/ml; NSE, \<3.4 or ≥3.4 ng/ml; CEA, \<17 or ≥17 ng/ml; and cytokeratin 19 fragment (Cyfra21-1), \<3.3 or ≥3.3 ng/ml\] were analyzed.

### CT image acquisition and pre-processing imaging environment

All patients underwent pulmonary CT examination using a Philips Brilliance 128i CT scanner (Philips Healthcare, Amsterdam, Netherlands). The tube voltage and current were 120 kV and 220 mA, respectively; the pitch was 1.0 and the collimator measured 64×0.625 mm. The acquired data were reconstructed into slices of 1.0 mm thickness at 1.0-mm intervals. The field of view was 20×20 cm. Prior to each scan, 1.5 ml/kg non-ionic contrast medium (Ultravist 300 mg I/ml; Schering Healthcare, Guangzhou, Guangdong, China) was injected into the antecubital vein using a 20G needle at a flow rate of 3 ml/sec. Saline (30--40 ml) was injected at the same flow rate. CT scanning was automatically triggered using a bolus-tracking technique following administration of the contrast agent. The region of interest was the pulmonary artery trunk and a threshold of 100 Hounsfield units was set. Scanning was triggered with a delay of 2 sec once the threshold was reached.

### Pre-processing

All original images captured prior to chemotherapy were in Digital Imaging and Communications in Medicine format (the international standard to transmit, store, retrieve, print, process and display medical imaging information). Prior to extraction of the quantitative radiomics features, the images required 3-dimensional (3D) manual segmentation. Itk-snap software (version 3.4; [www.itksnap.org](www.itksnap.org)) was used for this purpose. First, the abdominal window was contoured to identify its boundaries with the chest wall and other soft tissues. The pulmonary window was then contoured to capture the maximum extent of the tumor in the lung parenchyma ([@b25-etm-0-0-7357]). All tumors were manually segmented and completed independently by two radiologists with 11 and 20 years of experience in CT imaging of thoracic malignancies, respectively. Each radiologist reviewed the segmented images and any discrepancies were resolved by discussion until a consensus was reached. All images were normalized to gray values.

### Radiomic feature extraction

In SCLC, radiomic feature extraction is performed in 3D volumes of interest (VOIs) in order to calculate a set of statistical measures. These are then analyzed to determine which are statistically significant. The 3D VOIs were comprised of 3D regions of primary SCLC tumors. In each case, the 3D VOI was segmented manually by two experienced (≥10 years experience) radiologists. The radiologists delineated the boundaries of the primary tumors on a transversal plane using an in-house manual drawing program in MATLAB (version 7.0; The MathWorks, Inc. Natick, Massachusetts, USA).

In the present study, the CT images were processed using 3 different radiomic feature extraction strategies. The first method of gray level histogram analysis (GLHA) was used to calculate six parameters ([@b31-etm-0-0-7357]): Maximum, minimum, mean, standard deviation, skewedness and kurtosis of the CT values inside the 3D VOI. These parameters reflect the basic statistical characteristics of pixels inside tumors. However, they do not take into consideration the spatial information between adjacent pixels.

The second method of spatial gray-level dependence matrices (SGLDM) was used to calculate 10 statistical measures to quantify the differences between two adjacent pixels along specific directions: Entropy, angular second moment, contrast, homogeneity, sum-mean, variance, correlation maximum probability, inverse difference moment and cluster tendency. These parameters have been defined by previous studies ([@b32-etm-0-0-7357],[@b33-etm-0-0-7357]). They are calculated from 2D co-occurrence matrices, whose function Md(i, j) denotes the number of pairs of adjacent pixels with gray level i and with gray level j along the dth direction. As CT images are too thick for detailed analysis, only adjacent pixels within the same transverse plane were considered. In the present study, four directions along 0°, 45°, 90° and 135° were used.

The third method of neighborhood gray-tone difference matrices (NGTDM) calculated five statistical parameters: Coarseness, contrast, business, complexity and strength. They have also been defined previously ([@b34-etm-0-0-7357],[@b35-etm-0-0-7357]). This method differs from SGLDM, which quantified the associations between two adjacent pixels along given axes. Instead, this method describes how the gray level of a pixel differs from that of all its neighbors. The parameters were calculated on the basis of a neighborhood gray-level difference matrix M(i). The elements of this matrix consist of the differences between a pixel with gray level i and all of its neighbors. As in SGLDM, a pixel\'s neighbors are only defined along the same transverse plane. [Table I](#tI-etm-0-0-7357){ref-type="table"} presents the radiomic features of these parameters, including category, label, feature name and description. [Fig. 2](#f2-etm-0-0-7357){ref-type="fig"} presents a diagram of the method adopted in the present study.

### Statistical analysis

All statistical analyses were performed using SPSS version 19.0 (IBM Corp., Armonk, NY, USA). Student\'s t-tests were used for the comparison of two groups. Mann-Whitney U test was used to analyze the differences between each of the 21 computer-extracted features between the responsive and non-responsive two groups. Association between responsive and non-responsive groups and clinicopathological data from patients with SCLC was analyzed by Chi-square test. Binary logistic regression analysis was performed to assess the influence of the 21 computer-extracted indexes on the treatment efficacy. Receiver operating characteristic (ROC) curves were generated to determine the optimal cut-off threshold values. The area under the curve (AUC) ([@b36-etm-0-0-7357]) was used to evaluate the accuracy of the radiomics signature and the model in predicting the efficacy of chemotherapy. P≤0.05 was considered to indicate a statistically significant difference.

Results
=======

### Clinicopathological characteristics

The median age of the patients was 59 years (range, 22--83 years). Patients aged ≥60 years accounted for 43.5% of the study population and the majority of the patients were male (n=74; 80.4%). Smokers accounted for 69.6% of the population and 40 patients (43.5%) presented with distant metastasis ([Table II](#tII-etm-0-0-7357){ref-type="table"}).

### Association of clinicopathological factors with treatment efficacy

The smoking status in the response group was significantly associated with treatment efficacy compared with the no response group (P=0.05). However, there was no statistical significance in the smoking time (≤10, 11--20, 21--30 and ≥30 years, respectively; 38.6, 14.3, 22.8 and 24.3 vs. 13.6, 22.7, 27.3 and 36.4%) and smoking index (\<400 and ≥400, respectively; 47.1 and 52.9 vs. 27.3 and 72.7%) between the response and no response groups (P\>0.05; [Table II](#tII-etm-0-0-7357){ref-type="table"}). This may be due to the small size of the cohort, which limits the statistical power of the data.

### Association of the 21 radiomics characteristics with treatment efficacy

Univariate analysis revealed that, among the 21 radiological features analyzed, two features exhibited significant differences between the response and no response groups. The GLHA category had a maximum CT value, which was significantly different between the two groups (P=0.020). The inverse difference moment was observed in the SGLDM category, which was also significantly different between the two groups (P=0.037; [Table III](#tIII-etm-0-0-7357){ref-type="table"}).

Establishment of prediction models of the response to SCLC chemotherapy
-----------------------------------------------------------------------

### Prediction results of the radiomic features model

The radiomics signature model took into account 21 radiomics features. In the binary logistic regression analysis, backward logistic regression was adopted (R^2^=0.358). Analysis of the joint radiomics parameters revealed that the following 5 radiomics features exhibited significant differences: i) characteristics of the GLHA category \[standard deviation, P=0.003; odds ratio, 8.069; 95% confidence interval (CI), 2.077--31.340\]; ii) characteristics of the SGLDM category (contrast, P=0.005; odds ratio, 0.870; 95% CI, 0.790--0.959 and correlation, P=0.030; odds ratio, \<0.001; 95% CI 0--0.248); iii) characteristics of the NGTDM category (contrast, P=0.002; odds ratio, \<0.001, 95% CI, 0--0.001); and complexity (N4, P=0.002; odds ratio, 4.979; 95% CI, 1.790--13.847; [Table IV](#tIV-etm-0-0-7357){ref-type="table"}).

### Prediction results of the clinicopathological parameter model

The clinicopathological parameter model took into account conventional clinical risk factors (age ≥60 years, male sex, extensive tumor, central tumor, T1-3, N1-3, M1, smoking, smoking time, smoking index ≥400, ProGRP ≥54.8 ng/ml, NSE ≥3.4 ng/ml, CEA ≥17 ng/ml and Cyfra21-1 ≥3.3 ng/ml). For the binary logistic regression analysis, a backward logistic regression was adopted (R^2^=0.121). The results revealed that only smoking had a significant impact on the response to chemotherapy (P=0.038; 95% CI, 0.020--0.894; [Table V](#tV-etm-0-0-7357){ref-type="table"}).

### Predictive performance of the two models

The ROC curves of the radiomics signature model and clinicopathological parameter model were calculated using the significant variables in the logistic regression and are presented in [Fig. 3](#f3-etm-0-0-7357){ref-type="fig"}. The AUC of the radiomics signature was 0.797 (95% CI, 0.692--0.901). The AUC of the clinicopathological parameter model was 0.670 (95% CI, 0.547--0.793). Regarding the prediction of the accuracy of the efficacy of chemotherapy in patients with SCLC, the radiomics signature model was superior to the clinicopathological parameter model.

Discussion
==========

In the subgroup of current and former smokers, the lung cancer-associated mortality rate is highest at \~20%. Smoking is an important independent risk factor for SCLC and ≥90% of patients with SCLC are smokers ([@b1-etm-0-0-7357],[@b37-etm-0-0-7357]). In the present study, a significant difference in response to treatment between the smoking and non-smoking groups was identified. However, the smoking time and smoking index exhibited a similar trend but there was no significant difference observed. This may be due to the small size of the cohort, which limits the statistical power of the data. The results of the present study demonstrated that smoking was associated with the efficacy of chemotherapy in patients with SCLC. Thus, smoking cessation should be encouraged by clinicians.

At present, the tumor response is assessed by determining changes in tumor size (RECIST 1.1 is based on the diameter of the lesion). However, the tumor size does not truly reflect the morphological, functional and metabolic changes following tumor treatment, as necrosis, hemorrhage and cavitation frequently occur following chemotherapy ([@b38-etm-0-0-7357]). The present study, statistical analysis of primary tumor and radiomic texture characteristics may be used to predict the efficacy of chemotherapy in patients with SCLC. Such analyses constitute a powerful upgrade of the morphological assessment system, as indicated in a study on the pathological responses of lung cancer patients to chemotherapy ([@b39-etm-0-0-7357]).

Radiomics provides a non-invasive, rapid, cost-effective and reproducible method for detailed and comprehensive characterization of the tumor phenotypic information (shape, intensity, texture and wavelets) ([@b17-etm-0-0-7357]--[@b19-etm-0-0-7357],[@b36-etm-0-0-7357],[@b40-etm-0-0-7357],[@b41-etm-0-0-7357]). It may reduce the requirement for biopsy and it appears to offer a nearly limitless supply of imaging information that may potentially aid in the prediction of the response to chemotherapy as early as possible and, in turn, reduce unnecessary chemotherapy ([@b42-etm-0-0-7357]). Recently, radiomics has made a series of advances in tumor prediction. A radiomics signature has been demonstrated to be a biomarker for distant metastasis of lung adenocarcinoma (AUC=0.61) ([@b25-etm-0-0-7357]). It is able to predict histopathological features of lung carcinoma ([@b22-etm-0-0-7357],[@b23-etm-0-0-7357],[@b43-etm-0-0-7357],[@b44-etm-0-0-7357]), the recurrence of hepatocellular carcinoma (AUC=0.817) ([@b45-etm-0-0-7357]) and pre-operative prediction of lymph node metastasis in colorectal cancer (AUC=0.736) ([@b46-etm-0-0-7357]). Radiomics studies of lung cancer have mostly focused on non-SCLC ([@b20-etm-0-0-7357],[@b22-etm-0-0-7357]--[@b26-etm-0-0-7357],[@b43-etm-0-0-7357]); however, to the best of our knowledge, no previous study has investigated radiomics approaches in SCLC.

Radiomics features may be divided into four categories: Morphology, statistics, region and model. The statistical features of these categories may be classified as single-point statistics (histogram) or higher-order statistics (texture) ([@b47-etm-0-0-7357]). In the present study, 21 quantitative parameters were extracted from the statistical radiology characteristics. GLHA features constitute single-point statistics, which include 6 statistics (maximum of CT value, minimum of CT value, mean, standard deviation, skewedness and kurtosis) calculated from gray-level distributions (histogram) of voxels without considering spatial associations. SGLDM parameters include 10 statistics calculated from a co-occurrence matrix, characterizing variations of gray levels for a pair of consecutive voxels by considering spatial associations. NGTDM parameters use the intensity values of a neighborhood instead of one pixel to characterize differences in gray levels between a voxel and all its neighbors. SGLDM and NGTDM constitute higher-order statistics. They may be used to obtain information regarding the spatial association between pixels and thus reflect the textural characteristics of tumors. Ultimately, the five characteristics that exhibited significant differences between the effective and ineffective groups were included in the present model; the first- and higher-order statistics were included. Of note, the radiological features prediction model based on these features (AUC=0.797) had a higher predictive accuracy than the model of clinicopathological characteristics (AUC=0.670), indicating that radiomics features provide more information regarding heterogeneity within a tumor, and that the radiomics signature may successfully stratify chemotherapy patients into high- and low-risk groups. This would allow for the targeted and continued treatment of patients expected to exhibit a poor response to first-line chemotherapy, and may improve long-term patient survival.

In conclusion, the results of the present study revealed that a radiomics signature may be an independent predictor of the efficacy of chemotherapy in SCLC patients. It represents a novel biomarker that may be used for quantitative analysis in radiology and this information may help clinicians to better evaluate patients and select optimal treatment strategies.
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###### 

Information of the 21 radiomic features.

  Parameter category/label                   Feature name                Description
  ------------------------------------------ --------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gray level histogram analysis                                          
      G1                                     Maximum of CT value         Six statistics calculated on gray-level distribution (histogram) without considering spatial associations of voxels
      G2                                     Minimum of CT value         
      G3                                     Mean                        
      G4                                     Standard deviation          
      G5                                     Skewedness                  
      G6                                     Kurtosis                    
  Spatial gray-level dependence matrix                                   
      S1                                     Entropy                     Ten parameters calculated from co-occurrence matrix, characterizing variations of gray levels for a pair of consecutive voxels by considering spatial associations
      S2                                     Angular second moment       
      S3                                     Contrast                    
      S4                                     Homogeneity                 
      S5                                     Sum-mean                    
      S6                                     Variance                    
      S7                                     Correlation                 
      S8                                     Maximum probability         
      S9                                     Inverse difference moment   
      S10                                    Cluster tendency            
  Neighborhood gray-tone difference matrix                               
      N1                                     Coarseness                  Five parameters calculated from neighborhood Five parameters calculated from neighborhood gray.tone difference matrix, characterizing differences of gray levels between a voxel and all its neighbors
      N2                                     Contrast                    
      N3                                     Frequency of involvement    
      N4                                     Complexity                  
      N5                                     Intensity level             

CT, computed tomography.

###### 

Association between clinicopathological parameters and patient outcome for patients with SCLC.

  Parameter              Total (n=92)   Response group (n=70)   No response group (n=22)   P-value
  ---------------------- -------------- ----------------------- -------------------------- ---------
  Age (years)                                                                              0.830
    \<60                 52 (56.5)      40 (57.1)               12 (54.5)                  
    ≥60                  40 (43.5)      30 (42.9)               10 (45.5)                  
  Sex                                                                                      0.546
    Male                 74 (80.4)      55 (78.6)               19 (86.4)                  
    Female               18 (19.6)      15 (21.4)               3 (13.6)                   
  Tumor extent                                                                             0.845
    Limited              36 (39.1)      27 (38.6)               9 (40.9)                   
    Extensive            56 (60.9)      43 (61.4)               13 (59.1)                  
  Location                                                                                 0.206
    Central              76 (82.6)      60 (85.7)               16 (72.7)                  
    Peripheral           16 (17.4)      10 (14.3)               6 (27.3)                   
  T-stage                                                                                  0.485
    0                    18 (19.6)      13 (18.6)               5 (22.7)                   
    1                    26 (28.3)      18 (25.7)               8 (36.4)                   
    2                    30 (32.6)      23 (32.9)               7 (31.8)                   
    3                    18 (19.6)      16 (22.9)               2 (9.1)                    
  N-stage                                                                                  0.338
    0                    5 (5.4)        4 (5.7)                 1 (4.5)                    
    1                    11 (12.0)      6 (8.6)                 5 (22.7)                   
    2                    39 (42.4)      30 (42.9)               9 (40.9)                   
    3                    37 (40.2)      30 (42.9)               7 (31.8)                   
  M-stage                                                                                  0.206
    0                    52 (56.5)      37 (52.9)               15 (68.2)                  
    1                    40 (43.5)      33 (47.1)               7 (31.8)                   
  Smoking                                                                                  0.050
    No                   28 (30.4)      25 (35.7)               3 (13.6)                   
    Yes                  64 (69.6)      45 (64.3)               19 (86.4)                  
  Smoking index                                                                            0.100
    \<400                39 (42.4)      33 (47.1)               6 (27.3)                   
    ≥400                 53 (57.6)      37 (52.9)               16 (72.7)                  
  Smoking time (years)                                                                     0.378
    ≤10                  30 (32.6)      27 (38.6)               3 (13.6)                   
    11--20               15 (16.3)      10 (14.3)               5 (22.7)                   
    21--30               22 (23.9)      16 (22.9)               6 (27.3)                   
    ≥30                  25 (27.2)      17 (24.3)               8 (36.4)                   
  ProGRP (ng/ml)                                                                           0.078
    \<54.8               71 (77.2)      51 (72.9)               20 (90.9)                  
    ≥54.8                21 (22.8)      19 (27.1)               2 (9.1)                    
  NSE (ng/ml)                                                                              0.275
    \<3.4                19 (20.7)      13 (18.6)               6 (27.3)                   
    ≥3.4                 73 (79.3)      57 (81.4)               16 (72.7)                  
  CEA (ng/ml)                                                                              0.337
    \<17                 50 (54.3)      40 (57.1)               10 (45.5)                  
    ≥17                  42 (45.7)      30 (42.9)               12 (54.5)                  
  Cyfra21-1 (ng/ml)                                                                        0.512
    \<3.3                53 (57.6)      39 (55.7)               14 (63.6)                  
    ≥3.3                 39 (42.4)      31 (44.3)               8 (36.4)                   

Values are expressed as n (%). T-stage, tumor stage; N-stage, node stage; M-stage, metastasis stage; ProGRP, precursors of gastrin release peptide; NSE, neuronspecific enolase; CEA, carcinoembryonic antigen; Cyfra21-1, cytokeratin 19 fragment.

###### 

Univariate analysis of the 21 radiomic features associated with the chemotherapeutic effect introduced in [Table II](#tII-etm-0-0-7357){ref-type="table"}.

  Radiomic feature   Mean ± SD         Z        P-value
  ------------------ ----------------- -------- ---------
  G1                 119.750±12.976    −2.325   0.020
  G2                 1.110±4.835       −0.175   0.861
  G3                 63.080±4.222      −1.895   0.058
  G4                 9.600±4.677       −0.989   0.323
  G5                 −0.700±1.103      −1.071   0.284
  G6                 10.760±6.485      −1.510   0.131
  S1                 6.240±0.407       −0.622   0.534
  S2                 0.004±0.063       −0.201   0.840
  S3                 66.050±47.271     −1.565   0.118
  S4                 0.300±0.0357      −1.245   0.213
  S5                 64.370±4.199      −1.922   0.055
  S6                 102.410±168.990   −1.044   0.297
  S7                 0.570±0.111       −0.211   0.833
  S8                 0.015±0.030       −0.842   0.400
  S9                 0.200±0.037       −2.087   0.037
  S10                343.590±640.074   −0.86    0.390
  N1                 0.012±0.005       −0.32    0.749
  N2                 0.086±0.145       −1.556   0.120
  N3                 0.530±0.530       −0.137   0.891
  N4                 1.740±3.782       −0.824   0.410
  N5                 4.660±7.240       −0.165   0.869

Values are expressed as the mean ± standard deviation (n=92).

###### 

Prediction model of 21 radiomics features.

  Radiomic feature   β         Odds ratio (95% CI)     P-value
  ------------------ --------- ----------------------- ---------
  G2                 0.176     1.193 (0.940--1.514)    0.147
  G4                 2.088     8.069 (2.077--31.340)   0.003
  S3                 −0.139    0.870 (0.790--0.959)    0.005
  S5                 0.193     1.213 (0.962--1.531)    0.103
  S7                 −14.174   \<0.001 (0--0.248)      0.030
  N2                 −59.356   \<0.001 (0-\<0.001)     0.002
  N3                 1.661     5.266 (0.672--41.244)   0.114
  N4                 1.605     4.979 (1.790--13.847)   0.002

The radiomics model shows the results of 21 radiomics features (n=92). β, regression coefficient; CT, computed tomography; CI, confidence interval.

###### 

Multivariate analysis in the backward logistic regression model of clinicopathological parameters.

  Parameter                     β        Odds ratio (95% CI)     P-value
  ----------------------------- -------- ----------------------- ---------
  Gender (female)               −0.764   0.466 (0.056--3.869)    0.479
  Tumor extent (extensive)      −0.747   0.474 (0.113--1.996)    0.309
  Tumor location (peripheral)   −0.587   0.556 (0.124--2.482)    0.442
  T-stage (T0)                                                   0.323
    T1                          −1.173   0.309 (0.038--2.547)    0.275
    T2                          −1.903   0.149 (0.020--1.111)    0.063
    T3                          −1.296   0.274 (0.043--1.759)    0.172
  M-stage (M0)                  0.836    2.306 (0.599--8.877)    0.224
  Smoking (yes)                 −2.024   0.132 (0.020--0.894)    0.038
  ProGRP (≥54.8)                0.789    2.202 (0.385--12.600)   0.375
  NSE (≥3.4)                    0.651    1.917 (0.500--7.345)    0.342

The clinical model provides the results of multiple factors of clinical risk factors for small cell lung cancer (n=92). β, regression coefficient; T-stage, tumor-stage (T0); M-stage, metastasis stage (M0); ProGRP, precursors of gastrin release peptide; NSE, neuronspecific enolase; CI, confidence interval.

[^1]: Contributed equally
